Amjin waived its rights to leprosy and tuberculosis products

In 2019, Amkin spent $13.4 billion to acquire Otezla, a new drug for psoriasis arthritis® from New Base.
as part of the deal, Amgen also acquired AMG 634 (formerly known as CC-11050), but its commercial value was significantly lower.
now, Amjin has decided to sell the drug.
, Amgen and Australia's non-profit Global Health Drug Development (MDGH) Ltd. announced that they have signed a licensing agreement for AMG 634, a type 4 phosphate type 4 (PDE4) inhibitor that is being studied for the treatment of tuberculosis (TB) and leprosy-related erythema (ENL), the latter of which is caused by complications of leprosy in the skin and throughout the body.
M. Reese, Executive Vice President of Research and Development at
, said, "As TB and leprosy nod erythema remain challenging diseases in many countries around the world, AMSAM has been looking for an organization that can support the development of AMG 634 to address unseeded global health needs.
MDGH's track record and experience in product development, global health and neglected infectious diseases make it an ideal company for further development of AMG 634.
, an estimated 10 million people worldwide will be infected with TB in 2019, including more than 1 million children, and 1.4 million will die from TB, according to the World Health Organization.
, also known as Hansen's disease, affects the surface of the mucous membranes of the skin, the peripheral nerve upper respiratory tract and the eyes.
enL is an autoimmune complication that occurs many years after leprosy is cured and can lead to permanent nerve damage and disability.
AMG 634 is currently in phase 2 clinical research and development, led by the Aurum Institute NPC (for TB research) and the Nepal Institute for Leprosy (for ENL research).
the terms of the agreement, MDGH will be responsible for the further development and commercialization of AMG 634.
and Amiens will continue to support two Phase 2 clinical trials for ENL and TB, which will begin in 2021, to provide research drugs for both studies and to fund ENL research.
this support will help ensure a seamless transition to MDGH development for the transfer of the drug.
However, on the same day, Anjin and AstraZeneca's joint research and development of epithelial cytokine thymocytoplogen (TSLP) monoantigen tezepelumab failed in a critical Phase 3 study to maintain the treatment of severe asthma patients, which undoubtedly had an impact on Amgen's research product line.
the future fate of tezepelumab is still unknown, it is clear that the proceeds from the sale of AMG 634 will soon be invested in the development of new drugs that burn money and have unpredictable results.
source: 1.Amgen hands off rights to leprosy, tuberculosis meddled up as part of $13.4B Otezla deal 2.Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Development for Global Health